2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Cervical Cancer | Webinars & Videos
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Fast Company op-ed
Cervical Cancer | News & Updates
POV: The U.S. healthcare system is failing Black and Latina women
BD Onclarity™ HPV Assay with extended genotyping
Cervical Cancer | Brochures
BD Onclarity™ HPV Assay with extended genotyping